Trial reportClinical journal of the American Society of Nephrology : CJASN2008
N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients.
Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials.International urology and nephrology · 2013Pooled it
- The effect of N-acetyl cysteine injection on renal function after coronary artery bypass graft surgery: a randomized double blind clinical trial.Journal of cardiothoracic surgery · 2021Trial
- N-acetyl cysteine in prevention of amphotericin- induced electrolytes imbalances: a randomized, double-blinded, placebo-controlled, clinical trial.European journal of clinical pharmacology · 2014Trial
- Contrast-induced nephropathy and long-term adverse events: cause and effect?Clinical journal of the American Society of Nephrology : CJASN · 2009Trial
- Supplementation of Antioxidants in Chronic Kidney Disease: Clinical Necessity or Wishful Thinking? A Bench to Bedside Translational Research.Current medicinal chemistry · 2025Review
- N-Acetylcysteine Alleviates the Progression of Chronic Kidney Disease: A Three-Year Cohort Study.Medicina (Kaunas, Lithuania) · 2023Article
- N-Acetylcysteine: more than preventing contrast-induced nephropathy in uremic patients-focus on the antioxidant and anti-inflammatory properties.International urology and nephrology · 2023Review
- Molecular Mechanisms of Rhabdomyolysis-Induced Kidney Injury: From Bench to Bedside.Kidney international reports · 2023Review
- The dynamic clustering of insulin receptor underlies its signaling and is disrupted in insulin resistance.Nature communications · 2022Article
- A Systematic Review of the Effect of N-Acetylcysteine on Serum Creatinine and Cystatin C Measurements.Kidney international reports · 2021Article
- Massive acetaminophen overdose with metabolic acidosis refractory toToxicology reports · 2021Article
- Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Article
- N-acetylcysteine ameliorates contrast‑induced kidney injury in rats with unilateral hydronephrosis.Molecular medicine reports · 2018Article
- The Effect of N-Acetylcysteine on Creatinine Measurement: Protocol for a Systematic Review.Canadian journal of kidney health and disease · 2018Article
- Rosuvastatin attenuated contrast-induced nephropathy in diabetes patients with renal dysfunction.International journal of clinical and experimental medicine · 2015Article
- Oxidative stress, T cell DNA methylation, and lupus.Arthritis & rheumatology (Hoboken, N.J.) · 2014Article
- Section 3: Prevention and Treatment of AKI.Kidney international supplements · 2012Article
- Section 4: Contrast-induced AKI.Kidney international supplements · 2012Article
- How do centres begin the process to prevent contrast-induced acute kidney injury: a report from a new regional collaborative.BMJ quality & safety · 2012Article
- Farnesol in combination with N-acetylcysteine against Staphylococcus epidermidis planktonic and biofilm cells.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesN-acetylcysteine (NAC) has been widely used as a prophylactic therapy for contrast-induced nephropathy (CIN). Its efficacy is controversial because of heterogeneity in study results and because of evidence that NAC can alter serum creatinine levels without affecting glomerular filtration rate. This confounding effect of N-acetylcysteine on serum creatinine has not been rigorously tested, however, in a population at risk for CIN and following doses of NAC currently recommended for prophylaxis of CIN. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: "Double-dose" NAC was administered in the absence of iodinated contrast media to 29 stage 3 to 5 stable chronic kidney disease patients. Serum creatinine and cystatin C were measured before and 4 h and 48 h after the last dose of NAC.
resultsThere was no effect of NAC on either serum creatinine or cystatin C levels.
conclusionNAC, in doses currently recommended for prophylaxis of CIN, has no effect on serum creatinine or cystatin C levels. It is therefore unlikely that the heterogeneity seen in clinical trials of NAC prophylaxis for CIN is related to a confounding effect on serum creatinine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.